Skip to main content

NANOPARTICULAS MAGNETICAS AVANZAS PARA DETECCION Y CUANTIFICACION DE BIOMARCADORES EN FLUIDOS BIOLOGICOS

PCI2019-103715

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos Programación Conjunta Internacional
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE ALCALA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

New synthetic procedure for the antiviral sulfonate carbosilane dendrimer G2-S16 and its fluorescein-labelled derivative for biological studies

  • Gutiérrez Ulloa, Carlos Emilio
  • Peña González, Cornelia Emeritina|||0000-0002-9049-8804
  • Barrios Gumiel, Andrea
  • Ceña, Rafael
  • Serramía Lobera, María Jesús
  • Muñoz Fernández, María Ángeles
  • Mata de la Mata, Francisco Javier de la|||0000-0003-0418-3935
  • Sánchez-Nieves Fernández, Javier|||0000-0003-0410-2285
  • Gómez Ramírez, Rafael|||0000-0001-6448-2414
The anionic carbosilane (CBS) dendrimer with sulfonate groups G2-S16 is a promising compound for the preparation of a microbicide gel to prevent HIV infection. However, until now its synthesis required aggressive conditions. Hence, a reliable synthetic procedure is very important to face GMP conditions and clinical trials. In this study, G2-S16 has been prepared by a new approach that involves the addition of an amine-terminated dendrimer to ethenesulfonyl fluoride (C2H3SO3F, ESF) and then transformation to the sulfonate dendrimer by treatment with a base. This strategy also makes feasible the synthesis of a labelled sulfonate dendrimer (G2-S16-FITC) to be used as a molecular probe for in vivo experiments. Interestingly, G2-S16-FITC enters into human peripheral blood mononuclear cells (PBMCs)., Universidad de Alcalá, Ministerio de Economía, Industria y Competitividad, Comunidad de Madrid, Instituto de Salud Carlos III, Junta de Comunidades de Castilla-La Mancha